FR12C0034I2 - BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS A II RECEPTOR ANTAGONISTS - Google Patents

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS A II RECEPTOR ANTAGONISTS

Info

Publication number: FR12C0034I2
Authority: FR; France
Prior art keywords: receptor antagonists; benzimidazole derivatives; benzimidazole; derivatives; antagonists
Prior art date: 2004-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR12C0034C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Lim

Original Assignee

Takeda Pharmaceutical Co Lim

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2012-05-11

Publication date

2013-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-11 Application filed by Takeda Pharmaceutical Co Lim filed Critical Takeda Pharmaceutical Co Lim

2012-06-15 Publication of FR12C0034I1 publication Critical patent/FR12C0034I1/en

2013-01-11 Application granted granted Critical

2013-01-11 Publication of FR12C0034I2 publication Critical patent/FR12C0034I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pyrrole Compounds (AREA)

FR12C0034C 2004-02-25 2012-05-11 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS A II RECEPTOR ANTAGONISTS Active FR12C0034I2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004048928		2004-02-25
US11/031,057 US7157584B2 (en)	2004-02-25	2005-01-07	Benzimidazole derivative and use thereof
PCT/JP2005/003422 WO2005080384A2 (en)	2004-02-25	2005-02-23	Benzimidazole derivative and use as aii receptor antagonist

Publications (2)

Publication Number	Publication Date
FR12C0034I1 FR12C0034I1 (en)	2012-06-15
FR12C0034I2 true FR12C0034I2 (en)	2013-01-11

Family

ID=34858222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR12C0034C Active FR12C0034I2 (en)	2004-02-25	2012-05-11	BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS A II RECEPTOR ANTAGONISTS

Country Status (35)

Country	Link
US (3)	US7157584B2 (en)
EP (3)	EP2119715B1 (en)
JP (2)	JP4256852B2 (en)
KR (1)	KR101080029B1 (en)
CN (2)	CN100503605C (en)
AR (2)	AR047972A1 (en)
AT (2)	ATE440095T1 (en)
AU (1)	AU2005214271B8 (en)
BE (1)	BE2012C025I2 (en)
BR (2)	BR122012009489B8 (en)
CA (1)	CA2557538C (en)
CY (5)	CY1107008T1 (en)
DE (3)	DE602005002030T2 (en)
DK (3)	DK2119715T3 (en)
ES (3)	ES2331209T3 (en)
FR (1)	FR12C0034I2 (en)
HK (2)	HK1098472A1 (en)
HR (3)	HRP20070510T3 (en)
HU (1)	HUS1200008I1 (en)
IL (1)	IL177533A (en)
LU (1)	LU91962I2 (en)
MA (1)	MA28478B1 (en)
ME (2)	ME01089B (en)
MY (1)	MY142807A (en)
NL (1)	NL300802I2 (en)
NO (2)	NO332344B1 (en)
NZ (1)	NZ549755A (en)
PL (3)	PL1857457T3 (en)
PT (3)	PT2119715E (en)
RS (3)	RS51137B (en)
RU (2)	RU2501798C2 (en)
SI (3)	SI1857457T1 (en)
TW (1)	TWI336702B (en)
WO (1)	WO2005080384A2 (en)
ZA (1)	ZA200607241B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7157584B2 (en) *	2004-02-25	2007-01-02	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
CN101087619B (en)	2004-12-24	2012-12-05	西芬克斯医药有限公司	Method of treatment or prophylaxis
JP4465469B2 (en) *	2005-02-21	2010-05-19	国立大学法人佐賀大学	Interleukin 13 as a cardiovascular disease marker
MY146254A (en) *	2005-03-30	2012-07-31	Takeda Pharmaceutical	Benzimidazole derivative and use thereof
WO2007097452A1 (en) *	2006-02-27	2007-08-30	Takeda Pharmaceutical Company Limited	Medical blister package
WO2007097451A1 (en)	2006-02-27	2007-08-30	Takeda Pharmaceutical Company Limited	Pharmaceutical package
JP5230595B2 (en) *	2006-03-20	2013-07-10	スピニフェクスファーマシューティカルズピーティーワイリミテッド	Methods for treating or preventing inflammatory pain
JP5340925B2 (en) *	2006-09-25	2013-11-13	武田薬品工業株式会社	Pharmaceutical package
JP5283632B2 (en) *	2007-03-28	2013-09-04	武田薬品工業株式会社	Solid pharmaceutical composition containing a benzimidazole-7-carboxylate derivative and a pH adjuster
JP2009062296A (en) *	2007-09-05	2009-03-26	Fujifilm Corp	Method for producing carboxylic acid ester compound
ES2510866T3 (en) *	2008-03-13	2014-10-21	Daiichi Sankyo Company, Limited	Improvement of the solubility of a preparation containing olmesartan medoxomil
EP2310385B1 (en) *	2008-07-31	2017-06-07	Takeda Pharmaceutical Company Limited	Solid pharmaceutical composition
TW201014850A (en) *	2008-09-25	2010-04-16	Takeda Pharmaceutical	Solid pharmaceutical composition
EP2348857B1 (en) *	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075347A2 (en)	2008-12-23	2010-07-01	Takeda Pharmaceutical Company Limited	Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
UY33380A (en)	2010-05-11	2011-12-01	Janssen Pharmaceutica Nv	PHARMACEUTICAL FORMULATIONS CONTAINING DERIVATIVES OF 1- (B (BETA) -D-GLUCOPIRANOSILO) AND ITS USES
WO2012090043A1 (en) *	2010-12-29	2012-07-05	Jubilant Life Sciences Limited	Novel solid state forms of azilsartan medoxomil and preparation thereof
CN102603723B (en)	2011-01-20	2014-10-08	江苏豪森医药集团有限公司	Azilsartan organic amine salts, and preparation method and application thereof
WO2012107814A1 (en)	2011-02-08	2012-08-16	Jubilant Life Sciences Limited	An improved process for the preparation of azilsartan medoxomil
CN102138899B (en) *	2011-03-18	2013-08-21	海南本创医药科技有限公司	Olmesartan liposome solid preparation
ES2586846T3 (en)	2011-04-13	2016-10-19	Janssen Pharmaceutica, N.V.	Process of preparation of compounds useful as SGLT2 inhibitors
CN102827153B (en) *	2011-06-14	2016-10-05	江苏豪森药业集团有限公司	Crystal formation of Azilsartan and preparation method thereof
CN102351853B (en) *	2011-08-29	2014-03-12	石药集团欧意药业有限公司	Azilsartan medoxomil compound, preparation method and medicinal composition thereof
WO2013042066A1 (en) *	2011-09-20	2013-03-28	Ranbaxy Laboratories Limited	Process for the preparation of azilsartan medoxomil
WO2013042067A1 (en)	2011-09-20	2013-03-28	Ranbaxy Laboratories Limited	Process for the preparation of potassium salt of azilsartan medoxomil
AP2014007766A0 (en)	2011-12-15	2014-07-31	Takeda Pharmaceuticals Usa Inc	Combination os azilsartan and chlorthlidone for treating hypertension black patients
WO2013088384A2 (en)	2011-12-15	2013-06-20	Jubilant Life Sciences Limited	Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
WO2013104342A1 (en) *	2012-01-14	2013-07-18	Sunshine Lake Pharma Co., Ltd.	Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof
EP2814826A1 (en) *	2012-02-02	2014-12-24	Ranbaxy Laboratories Limited	Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (en) *	2012-02-20	2013-08-29	Alembic Pharmaceuticals Limited	Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (en) *	2012-04-19	2013-10-30	Zentiva, K.S.	Process for preparing extremely pure potassium salt of azilsartan medoxomil
WO2013186792A2 (en) *	2012-06-11	2013-12-19	Msn Laboratories Limited	Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
CA2884248A1 (en) *	2012-07-09	2014-01-16	Hetero Research Foundation	Novel polymorphs of azilsartan
WO2014020381A1 (en) *	2012-08-01	2014-02-06	Alembic Pharmaceuticals Limited	Novel crystalline form of azilsartan medoxomil potassium
EP2925753A4 (en) *	2012-08-27	2017-02-15	Hetero Research Foundation	Novel polymorphs of azilsartan medoxomil
CZ305318B6 (en) *	2012-09-26	2015-07-29	Zentiva, K.S.	Process for preparing extremely pure azilsartan medoxomil potassium salt
WO2014049512A2 (en)	2012-09-26	2014-04-03	Lupin Limited	Novel process for preparation of azilsartan medoxomil
CN103709154B (en) *	2012-09-28	2016-06-15	武汉朗来科技发展有限公司	Benzimidizole derivatives and preparation method thereof and medical usage
AU2013329253B2 (en) *	2012-10-09	2017-02-23	Avery Dennison Corporation	Adhesives and related methods
CN103910720A (en) *	2013-01-07	2014-07-09	广东东阳光药业有限公司	Novel crystal form of azilsartan medoxomil and preparation method thereof
CN105153141B (en) *	2013-02-04	2018-09-25	武汉朗来科技发展有限公司	Benzimidizole derivatives and preparation method thereof and medical usage
JP6281735B2 (en) *	2013-03-19	2018-02-21	トーアエイヨー株式会社	Method for evaluating therapeutic agent for acute heart failure and method for producing acute heart failure model
RU2535004C1 (en) *	2013-06-11	2014-12-10	Николай Андреевич Козлов	Method of treatment intervertebral disk disease in dogs
RU2535005C1 (en) *	2013-06-11	2014-12-10	Николай Андреевич Козлов	Method of treatment of intervertebral disk diseases in dogs
CN104812752B (en) *	2013-10-12	2016-09-28	杭州领业医药科技有限公司	Crystal formation of Azilsartan and preparation method thereof
CN105949183B (en) *	2013-10-12	2019-02-22	杭州领业医药科技有限公司	Crystal form of Azilsartan and preparation method thereof
CN104774197B (en) *	2014-01-09	2017-11-17	武汉朗来科技发展有限公司	A kind of preparation method of benzimidizole derivatives
CN104774196B (en) *	2014-01-09	2017-11-10	武汉朗来科技发展有限公司	A kind of preparation method of benzimidizole derivatives
CN105079815A (en) *	2014-04-30	2015-11-25	广东东阳光药业有限公司	A kind of azilsartan medoxomil potassium composition and preparation method thereof
CN104016974A (en) *	2014-06-24	2014-09-03	浙江天宇药业股份有限公司	Azilsartan medoxomil intermediates and synthetic methods thereof, as well as synthetic method of azilsartan medoxomil
CZ2014702A3 (en)	2014-10-15	2016-04-27	Zentiva, K.S.	Process for preparing extremely pure azilsartan
CN105622595A (en) *	2014-11-21	2016-06-01	重庆朗天制药有限公司	Novel preparation method of azilsartan medoxomil sylvite and its intermediate
CN105753854A (en) *	2014-12-16	2016-07-13	重庆朗天制药有限公司	New preparation method of azilsartan kamedoxomil
WO2016145622A1 (en)	2015-03-18	2016-09-22	武汉朗来科技发展有限公司	Benzimidazole derivatives, preparation method therefor and medicinal use thereof
CN106032378B (en) *	2015-03-20	2019-10-25	武汉启瑞药业有限公司	New A RB compound and application thereof
CN104803998B (en) *	2015-03-26	2017-08-25	晋江市托美汀生物科技有限公司	A kind of method for reducing impurity content
US20200179369A1 (en) *	2015-07-29	2020-06-11	Takeda Gmbh	Treatment of diabetic nephropathy
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (en) *	2016-11-30	2021-04-07	株式会社トクヤマ	Manufacturing method of azilsartan
WO2017131218A1 (en) *	2016-01-28	2017-08-03	株式会社トクヤマ	Azilsartan and method for producing same
CN105628824B (en) *	2016-03-06	2017-10-17	江苏正大清江制药有限公司	About the method for material in a kind of high effective liquid chromatography for measuring Azilsartan raw material
CN107400122B (en) *	2016-05-20	2020-10-23	武汉朗来科技发展有限公司	Compound, preparation method, composition and application thereof
CN105770876B (en) *	2016-05-30	2019-09-10	广东天普生化医药股份有限公司	Purposes of the ulinastatin in preparation treatment chronic prostatitis drug
EP3461822B1 (en) *	2016-07-11	2022-11-02	Wuhan LL Science And Technology Development Co., Ltd.	Crystalline form of chemical compound, and preparation method, composition, and application thereof
RU2623082C1 (en) *	2016-07-11	2017-06-21	Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Method for arterial rigidity correction in patients with rheumatoid arthritis
RU2634272C1 (en) *	2016-08-10	2017-10-24	Закрытое акционерное общество "Санкт-Петербургский институт фармации"	Composition with desamino-arginine vasotocin for parenteral introduction and method for its production
CN106074416A (en) *	2016-08-30	2016-11-09	佛山市弘泰药物研发有限公司	A kind of preparation method of Azilsartan potassium salt dispersible tablet
WO2018064945A1 (en) *	2016-10-08	2018-04-12	武汉朗来科技发展有限公司	Pharmaceutical composition
IN201721047406A (en)	2017-12-30	2020-06-19	Lupin Limited
CN110237072B (en) *	2018-03-09	2022-03-25	武汉朗来科技发展有限公司	Process for preparing pharmaceutical composition
CN110237071B (en) *	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	Pharmaceutical preparation and use thereof
EP3807892A1 (en) *	2018-06-14	2021-04-21	AstraZeneca UK Limited	Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
WO2019241590A1 (en)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
WO2020101450A1 (en)	2018-11-16	2020-05-22	엠에프씨 주식회사	Derivative compounds of azilsartan, intermediates thereof, preparation method therefor, and pharmaceutical composition comprising same
EP3925957A4 (en) *	2019-02-15	2022-11-02	Tohoku University	1,3-DIOXOLEAN DERIVATIVE
KR102220011B1 (en)	2020-05-15	2021-02-25	대봉엘에스 주식회사	Method for preparing azilsartan with environment-friendly solvent, and key intermediate compounds thereof
CN113912580B (en) *	2021-11-03	2023-06-02	瑞孚信江苏药业股份有限公司	Method for purifying 4- (hydroxymethyl) -5-methyl- [1,3] dioxol-2-one
AU2022428746A1 (en)	2021-12-28	2024-04-04	Alchemedicine, Inc.	Compound, angiotensin II type 1 receptor antagonist and pharmaceutical composition
KR20240039252A (en)	2022-09-19	2024-03-26	대봉엘에스 주식회사	Azilsartan dicyclohexylamine as an angiotensin ⅱ antagonist, and pharmaceutical composition comprising the same as an active ingredient for preventing or treating cardiovascular disease
WO2024109927A1 (en) *	2022-11-24	2024-05-30	上海云晟研新生物科技有限公司	Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62290071A (en)	1986-06-09	1987-12-16	Matsushita Electric Ind Co Ltd	Organic electrolyne secondary battery
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2061607C (en)	1991-02-21	1999-01-19	Hiroaki Yanagisawa	1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) *	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en) *	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
RU2117668C1 (en) *	1991-10-23	1998-08-20	Эйсаи Ко., Лтд.	Oxazolidone derivative or its pharmacologically acceptable salts, pharmaceutical composition, method of treatment
US5310929A (en) *	1992-08-06	1994-05-10	E. I. Du Pont De Nemours And Company	Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
JP2787539B2 (en) *	1993-02-26	1998-08-20	松森　　昭	Agent for preventing or treating viral diseases
TW403748B (en) *	1994-11-02	2000-09-01	Takeda Chemical Industries Ltd	An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) *	1995-04-03	1997-03-11	Bristol-Myers Squibb Company	Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
IL153633A0 (en)	2000-07-13	2003-07-06	Takeda Chemical Insustries Ltd	Lipid-rich plaque inhibitors
AU2002349673A1 (en) *	2001-12-03	2003-06-17	Takeda Chemical Industries, Ltd.	Insulin resistance improving agents
CN1615305A (en)	2002-01-11	2005-05-11	武田药品工业株式会社	Coumarin derivatives, process for their production and use thereof
US20070004736A1 (en)	2002-11-22	2007-01-04	Keiji Kubo	Imidazole derivative, process for producing the same, and use
US6972258B2 (en) *	2003-08-04	2005-12-06	Taiwan Semiconductor Manufacturing Co., Ltd.	Method for selectively controlling damascene CD bias
US7157584B2 (en) *	2004-02-25	2007-01-02	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
JP4364171B2 (en)	2005-07-15	2009-11-11	本田技研工業株式会社	Automotive door checker
UA58542U (en) *	2010-12-16	2011-04-11	Леонид Борисович Борейко	Method of clamping a recovery vehicle while pulling a heavy stuck car

2005
- 2005-01-07 US US11/031,057 patent/US7157584B2/en active Active
- 2005-02-23 ES ES07075609T patent/ES2331209T3/en not_active Expired - Lifetime
- 2005-02-23 CA CA2557538A patent/CA2557538C/en not_active Expired - Lifetime
- 2005-02-23 EP EP08075903A patent/EP2119715B1/en not_active Expired - Lifetime
- 2005-02-23 EP EP05719737A patent/EP1718641B1/en not_active Expired - Lifetime
- 2005-02-23 RS RSP-2009/0484A patent/RS51137B/en unknown
- 2005-02-23 DK DK08075903.8T patent/DK2119715T3/en active
- 2005-02-23 WO PCT/JP2005/003422 patent/WO2005080384A2/en active Application Filing
- 2005-02-23 PT PT08075903T patent/PT2119715E/en unknown
- 2005-02-23 RU RU2009115498/04A patent/RU2501798C2/en active Protection Beyond IP Right Term
- 2005-02-23 AR ARP050100653A patent/AR047972A1/en active IP Right Grant
- 2005-02-23 KR KR1020067016710A patent/KR101080029B1/en active Protection Beyond IP Right Term
- 2005-02-23 RU RU2006133898/04A patent/RU2369608C2/en active Protection Beyond IP Right Term
- 2005-02-23 CN CNB2005800130733A patent/CN100503605C/en not_active Expired - Lifetime
- 2005-02-23 MY MYPI20050690A patent/MY142807A/en unknown
- 2005-02-23 PT PT07075609T patent/PT1857457E/en unknown
- 2005-02-23 PL PL07075609T patent/PL1857457T3/en unknown
- 2005-02-23 AU AU2005214271A patent/AU2005214271B8/en active Active
- 2005-02-23 DK DK07075609T patent/DK1857457T3/en active
- 2005-02-23 NZ NZ549755A patent/NZ549755A/en unknown
- 2005-02-23 SI SI200530822T patent/SI1857457T1/en unknown
- 2005-02-23 ME MEP-2009-323A patent/ME01089B/en unknown
- 2005-02-23 RS RS20120362A patent/RS52376B/en unknown
- 2005-02-23 RS RSP-2007/0448A patent/RS50537B/en unknown
- 2005-02-23 AT AT07075609T patent/ATE440095T1/en active
- 2005-02-23 AT AT05719737T patent/ATE370136T1/en active
- 2005-02-23 PL PL05719737T patent/PL1718641T3/en unknown
- 2005-02-23 DK DK05719737T patent/DK1718641T3/en active
- 2005-02-23 EP EP07075609A patent/EP1857457B1/en not_active Expired - Lifetime
- 2005-02-23 ES ES08075903T patent/ES2388945T3/en not_active Expired - Lifetime
- 2005-02-23 PT PT05719737T patent/PT1718641E/en unknown
- 2005-02-23 SI SI200530072T patent/SI1718641T1/en unknown
- 2005-02-23 ES ES05719737T patent/ES2293552T3/en not_active Expired - Lifetime
- 2005-02-23 JP JP2005047294A patent/JP4256852B2/en not_active Expired - Lifetime
- 2005-02-23 BR BR122012009489A patent/BR122012009489B8/en active IP Right Grant
- 2005-02-23 DE DE602005002030T patent/DE602005002030T2/en active Active
- 2005-02-23 ME MEP-2007-448A patent/ME01643B/en unknown
- 2005-02-23 BR BRPI0507984A patent/BRPI0507984B8/en active IP Right Grant
- 2005-02-23 SI SI200531568T patent/SI2119715T1/en unknown
- 2005-02-23 PL PL08075903T patent/PL2119715T3/en unknown
- 2005-02-23 DE DE602005016162T patent/DE602005016162D1/en active Active
- 2005-02-23 CN CN2008101701465A patent/CN101381366B/en not_active Expired - Lifetime
- 2005-02-23 TW TW094105364A patent/TWI336702B/en active
2006
- 2006-08-16 IL IL177533A patent/IL177533A/en active IP Right Grant
- 2006-08-23 US US11/466,633 patent/US7572920B2/en not_active Expired - Lifetime
- 2006-08-30 ZA ZA2006/07241A patent/ZA200607241B/en unknown
- 2006-09-20 NO NO20064251A patent/NO332344B1/en active Protection Beyond IP Right Term
- 2006-09-22 MA MA29333A patent/MA28478B1/en unknown
2007
- 2007-05-04 HK HK07104818A patent/HK1098472A1/en unknown
- 2007-11-05 HR HR20070510T patent/HRP20070510T3/en unknown
- 2007-11-14 CY CY20071101476T patent/CY1107008T1/en unknown
2008
- 2008-04-29 HK HK08104744.3A patent/HK1115118A1/en unknown
- 2008-12-22 JP JP2008325152A patent/JP2009137974A/en active Pending
2009
- 2009-06-30 US US12/458,092 patent/US7875637B2/en not_active Expired - Lifetime
- 2009-11-04 HR HR20090593T patent/HRP20090593T1/en unknown
- 2009-11-12 CY CY20091101184T patent/CY1109610T1/en unknown
2012
- 2012-03-21 LU LU91962C patent/LU91962I2/en unknown
- 2012-03-29 DE DE201212000018 patent/DE122012000018I1/en active Pending
- 2012-05-11 FR FR12C0034C patent/FR12C0034I2/en active Active
- 2012-05-17 HU HUS1200008C patent/HUS1200008I1/en unknown
- 2012-05-31 CY CY2012015C patent/CY2012015I1/en unknown
- 2012-05-31 CY CY2012016C patent/CY2012016I1/en unknown
- 2012-06-07 BE BE2012C025C patent/BE2012C025I2/fr unknown
- 2012-08-17 HR HRP20120667TT patent/HRP20120667T2/en unknown
- 2012-08-29 CY CY20121100774T patent/CY1113084T1/en unknown
- 2012-11-09 NO NO2012017C patent/NO2012017I1/en not_active IP Right Cessation
2014
- 2014-01-27 AR ARP140100236A patent/AR094588A2/en not_active Application Discontinuation
2016
- 2016-03-15 NL NL300802C patent/NL300802I2/nl unknown

Also Published As

Publication number	Publication date
DE602005002030D1 (en)	2007-09-27
RU2501798C2 (en)	2013-12-20
EP1857457A2 (en)	2007-11-21
CY1109610T1 (en)	2014-08-13
EP1857457B1 (en)	2009-08-19
JP2005272451A (en)	2005-10-06
HRP20070510T3 (en)	2007-12-31
DK1857457T3 (en)	2009-12-21
ES2293552T3 (en)	2008-03-16
KR20070020411A (en)	2007-02-21
RU2369608C2 (en)	2009-10-10
HRP20120667T1 (en)	2012-09-30
JP2009137974A (en)	2009-06-25
ME01089B (en)	2013-03-20
MA28478B1 (en)	2007-03-01
NO2012017I1 (en)	2012-11-26
ATE440095T1 (en)	2009-09-15
AU2005214271B2 (en)	2011-02-24
BR122012009489B1 (en)	2019-02-19
BRPI0507984A (en)	2007-07-24
CY1107008T1 (en)	2012-09-26
FR12C0034I1 (en)	2012-06-15
HRP20090593T1 (en)	2010-03-31
BR122012009489B8 (en)	2023-03-21
IL177533A (en)	2010-12-30
CN101381366A (en)	2009-03-11
CY2012015I2 (en)	2016-12-14
EP2119715B1 (en)	2012-05-30
PT2119715E (en)	2012-09-03
SI2119715T1 (en)	2012-10-30
CN1946717A (en)	2007-04-11
ATE370136T1 (en)	2007-09-15
NO20064251L (en)	2006-11-22
ME01643B (en)	2010-05-07
NO2012017I2 (en)	2012-11-09
TW200530227A (en)	2005-09-16
HK1098472A1 (en)	2007-07-20
PL2119715T3 (en)	2012-10-31
RS51137B (en)	2010-10-31
SI1857457T1 (en)	2010-01-29
DE122012000018I1 (en)	2012-06-06
EP1857457A3 (en)	2007-12-05
BRPI0507984B1 (en)	2018-07-03
AU2005214271B8 (en)	2011-03-03
CN101381366B (en)	2011-06-15
CY2012016I2 (en)	2016-12-14
CY1113084T1 (en)	2016-04-13
ZA200607241B (en)	2008-04-30
HK1115118A1 (en)	2008-11-21
AU2005214271A1 (en)	2005-09-01
US7875637B2 (en)	2011-01-25
JP4256852B2 (en)	2009-04-22
WO2005080384A9 (en)	2006-11-30
HUS1200008I1 (en)	2017-06-28
ES2331209T3 (en)	2009-12-23
NL300802I2 (en)	2016-05-18
TWI336702B (en)	2011-02-01
CN100503605C (en)	2009-06-24
KR101080029B1 (en)	2011-11-04
SI1718641T1 (en)	2007-12-31
US7157584B2 (en)	2007-01-02
CA2557538C (en)	2010-08-17
AU2005214271A2 (en)	2005-09-01
NZ549755A (en)	2009-04-30
RS50537B (en)	2010-05-07
PL1857457T3 (en)	2009-12-31
ES2388945T3 (en)	2012-10-22
US20090270464A1 (en)	2009-10-29
US7572920B2 (en)	2009-08-11
DK1718641T3 (en)	2007-12-17
DE602005016162D1 (en)	2009-10-01
PL1718641T3 (en)	2008-01-31
US20060281795A1 (en)	2006-12-14
AR047972A1 (en)	2006-03-15
IL177533A0 (en)	2006-12-10
HRP20120667T2 (en)	2012-11-30
CY2012016I1 (en)	2016-12-14
MY142807A (en)	2011-01-14
AR094588A2 (en)	2015-08-12
EP1718641B1 (en)	2007-08-15
CA2557538A1 (en)	2005-09-01
DE602005002030T2 (en)	2008-05-08
US20050187269A1 (en)	2005-08-25
EP1718641A2 (en)	2006-11-08
EP2119715A1 (en)	2009-11-18
DK2119715T3 (en)	2012-09-10
BRPI0507984B8 (en)	2023-03-21
BE2012C025I2 (en)	2024-08-08
PT1857457E (en)	2009-09-23
RU2006133898A (en)	2008-03-27
CY2012015I1 (en)	2016-12-14
RU2009115498A (en)	2010-10-27
WO2005080384A3 (en)	2006-09-28
RS52376B (en)	2012-12-31
NO332344B1 (en)	2012-09-03
PT1718641E (en)	2007-11-15
LU91962I2 (en)	2012-05-21
WO2005080384A2 (en)	2005-09-01

Publication	Publication Date	Title
FR12C0034I2 (en)	2013-01-11	BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS A II RECEPTOR ANTAGONISTS
DK1720859T3 (en)	2010-04-26	Chemokine receptor antagonists
EP2150115A4 (en)	2011-08-03	RECEPTOR ANTAGONISTS OF CYCLOPROPYLPYRROLIDINE OREXINE
DK2081951T3 (en)	2010-08-09	Progesterone receptor antagonists
PL2513093T3 (en)	2015-03-31	New CCR2 receptor antagonists and their application
DK1973886T3 (en)	2013-03-18	PROKINETICIN-1 Receptor Antagonists
BRPI0817245A2 (en)	2015-06-16	Derivatives and quinoline as 5ht5a receptor antagonists
EP1959959A4 (en)	2011-09-21	MORPHOLINE-carboxamide-Prokineticin Receptor Antagonists
EP1641781A4 (en)	2010-06-23	BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS
MA28359A1 (en)	2006-12-01	ANTAGONISTS OF THE HYDROISOINDOLINE TACHYKININ RECEPTOR
DK2094709T3 (en)	2010-12-06	Thiazole-pyrazolopyrimidines as CRF1 receptor antagonists
EP1954268A4 (en)	2010-11-03	SPIROLACTAM BICYCLIC BCRP RECEPTOR ANTAGONISTS
MA28815B1 (en)	2007-08-01	INDOLE-2-CARBOXAMIDINE DERIVATIVES AS ANTAGONISTS OF THE NMDA RECEPTOR
EP1951042A4 (en)	2010-11-03	SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
IL237513A0 (en)	2015-04-30	Piperazinediones as oxytocin receptor antagonists
EP1799672A4 (en)	2011-01-19	CGRP RECEPTOR ANTAGONISTS
BRPI0820633A2 (en)	2019-09-24	Modified il-4 mutein receptor antagonists
EP1951228A4 (en)	2010-11-03	SPIROHYDANTOIN BICLYCLIC CGRP RECEPTOR ANTAGONISTS
ATE414078T1 (en)	2008-11-15	INDOL-3-YLCARBONYLPIPERIDINE BENZIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS
EP2150248A4 (en)	2011-06-29	GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE
DE602005009355D1 (en)	2008-10-09	DISABLED HIMBACINANALOGA AS THROMBIN RECEPTOR ANTAGONISTS
IS8278A (en)	2006-01-31	Cycopropyl derivatives as NK3 receptor antagonists
EP2067480A4 (en)	2009-11-25	MUSCLIN RECEPTOR AND USE THEREOF
EP1534736A4 (en)	2006-11-02	NOGO RECEPTOR ANTAGONISTS
DE602005007719D1 (en)	2008-08-07	ANTAGONISTS OF THE OPIOID RECEPTOR